FTY720 and Cyclosporine: Evaluation for a Pharmacokinetic Interaction

Abstract

Spanish

French

BACKGROUND:

FTY720 is a sphingosine-1-phosphate receptor agonist intended for use in immunoprophylaxis regimens to prevent acute rejection after organ transplantation.

OBJECTIVE:

To evaluate the potential for a pharmacokinetic drug interaction between the immunomodulator FTY720 and cyclosporine to support the use of this drug combination in organ transplantation.

METHODS:

In this open-label, randomized crossover study, 12 subjects with psoriasis received a single dose of FTY720 1 mg alone and on day 5 of an 8-day course of cyclosporine 200 mg twice daily. The single-dose pharmacokinetics of FTY720 and the steady-state pharmacokinetics of cyclosporine were characterized when given alone and during coadministration. Routine safety data were collected, with special attention to total blood lymphocyte counts and heart rate.

RESULTS:

Cyclosporine coadministration compared with FTY720 given alone did not significantly alter FTY720 maximum concentration (C_max) (0.57 ± 0.17 vs 0.58 ± 0.19 • ng/mL, respectively) or AUC_0-t (41 ± 13 vs 41 ± 13 ng • h/mL, respectively). Likewise for cyclosporine, FTY720 coadministration did not alter the steady-state C_max compared with cyclosporine given alone (1452 ± 308 vs 1376 ± 149 ng/mL, respectively) or AUC_τ (6385 ± 1578 vs 6031 ± 1051 ng • h/mL, respectively). Mean lymphocyte counts decreased from baseline by an average of 35% over the first 2 days after FTY720 administration and thereafter increased to prestudy values by day 5 similarly in the absence and presence of cyclosporine. The morning mean supine heart rate decreased approximately 10% and returned to prestudy rates by day 5 after administration of FTY720 alone and with cyclosporine. Heart rate changes were asymptomatic in all study participants. One subject experienced asymptomatic second-degree type 1 atrioventricular (Wenckebach) block.

CONCLUSIONS:

The pharmacokinetics of single-dose FTY720 and steady-state cyclosporine were not altered during coadministration.

Keywords

cyclosporine drug interactions FTY720 immunosuppressants

Get full access to this article

View all access options for this article.

References

Brinkmann

Lynch

FTY720: Targeting G-protein—coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002;14:569–75.

Pinschewer

Ochsenbein

Odermatt

Brinkmann

Hengartner

Zinkernagel

RM.

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761–70.

Zimmerlin

Patten

Role of CYP4F in the metabolic clearance of FTY720: Prediction of low drug—drug interaction potential (abstract 300). Am J Transplant 2000;1(suppl 1):S191.

Kovarik

Schmouder

Barilla

Wang

Kraus

Single-dose FTY720 pharmacokinetics, food effect, and pharmacologic response in healthy subjects. Br J Clin Pharmacol 2004;57:586–91.

Tucker

Houston

Huang

SM.

Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential—towards a consensus. Br J Clin Pharmacol 2001;52:107–17.

Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations (revision 1). Rockville, MD: Food and Drug Administration, 2003.

Budde

Schmouder

Brunkhorst

Nashan

Lücker

Mayer

First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13:1073–83.

Kahan

Karlix

Ferguson

Leichtman

Mulgaonkar

Gonwa

Pharmacodynamics, pharmacokinetics, and safety of multiple-doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, Phase 1 study. Transplantation 2003;76:1079–84.

Guo

MacDonell

Giles

WR.

Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Eur J Physiol 1999;438:642–8.